ArticleInternational journal of nephrology2012
Understanding nephrogenic systemic fibrosis.
Article in International journal of nephrology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- MRI Directed Magnevist Effective to Study Toxicity of Gd-Doped Mesoporous Carbon Nanoparticles in Mice Model.International journal of nanomedicine · 2023Article
- Recent Advances in Gadolinium Based Contrast Agents for Bioimaging Applications.Nanomaterials (Basel, Switzerland) · 2021Review
- Nephrogenic systemic fibrosis: A frivolous entity.World journal of nephrology · 2021Review
- Neutrophil elastase in the development of nephrogenic systemic fibrosis (NSF)-like skin lesion in renal failure mouse model.PloS one · 2021Article
- Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review.Clinical reviews in allergy & immunology · 2017Review
- Photopheresis Provides Significant Long-Lasting Benefit in Nephrogenic Systemic Fibrosis.Case reports in dermatological medicine · 2017Article
- Renal-related adverse effects of intravenous contrast media in computed tomography.Singapore medical journal · 2015Review
- Molecular Imaging with MRI: Potential Application in Pancreatic Cancer.BioMed research international · 2015Review
- Diffusion-weighted MR imaging for the diagnosis of abscess complicating fistula-in-ano: preliminary experience.European radiology · 2014Article
- Hemodynamic analysis of renal artery stenosis using computational fluid dynamics technology based on unenhanced steady-state free precession magnetic resonance angiography: preliminary results.The international journal of cardiovascular imaging · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nephrogenic systemic fibrosis (NSF) is a rare and a debilitating disease noted uncommonly in patients with impaired renal function when exposed to low-stability gadolinium-based contrast agents (Gd-CAs). According to experimental studies, cytokines released by the stimulation of effector cells such as skin macrophages and peripheral blood monocytes activate circulating fibroblasts which play a major role in the development of NSF lesions. The presence of permissive factors, presumably, provides an environment conducive to facilitate the process of fibrosis. Multiple treatment modalities have been tried with variable success rates. More research is necessary to elucidate the underlying pathophysiological mechanisms which could potentially target the initial steps of fibrosis in these patients. This paper attempts to collate the inferences from the in vivo and in vitro experiments to the clinical observations to understand the pathogenesis of NSF. Schematic representations of receptor-mediated molecular pathways of activation of macrophages and fibroblasts by gadolinium and the final pathway to fibrosis are incorporated in the discussion.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.